Sugi Predict

Sugi Predict / Targets / TTK

TTK

Dual specificity protein kinase TTK · P33981 · TTK on Sugi Atlas →

83,802 patent compounds predicted against TTK, 47,640 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL104312 SCHEMBL104312 1.00 20/20
SCHEMBL104317 SCHEMBL104317 1.00 20/20
SCHEMBL104472 SCHEMBL104472 1.00 20/20
SCHEMBL104765 SCHEMBL104765 1.00 20/20
SCHEMBL105020 SCHEMBL105020 1.00 20/20
SCHEMBL105196 SCHEMBL105196 1.00 20/20
SCHEMBL137089 SCHEMBL137089 1.00 20/20
SCHEMBL104910 SCHEMBL104910 0.90 20/20
SCHEMBL135281 SCHEMBL135281 0.88 20/20
SCHEMBL104134 SCHEMBL104134 0.87 20/20
SCHEMBL104724 SCHEMBL104724 0.85 20/20
SCHEMBL104887 SCHEMBL104887 0.82 20/20
SCHEMBL104544 SCHEMBL104544 0.81 20/20
SCHEMBL104539 SCHEMBL104539 0.79 20/20
SCHEMBL134558 SCHEMBL134558 0.78 20/20
SCHEMBL134559 SCHEMBL134559 0.77 20/20
SCHEMBL104538 SCHEMBL104538 0.77 20/20
SCHEMBL105105 SCHEMBL105105 0.77 20/20
SCHEMBL178456 SCHEMBL178456 0.77 20/20
SCHEMBL178466 SCHEMBL178466 0.77 20/20

Clinical trials — most relevant to TTK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer PHASE2RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Protein Tyrosine Kinases (PTK) in Multiple Myeloma PHASE2COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy PHASE2COMPLETED
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma PHASE1/PHASE2COMPLETED
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP PHASE1/PHASE2COMPLETED
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma PHASE2ACTIVE_NOT_RECRUITING
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors PHASE1UNKNOWN
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Androgenetic Alopecia and the JAK-STAT Pathway nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TTK binder may also engage these)

ProteinNameSimilarity
Q4R945 — 1.000 Q4R945 →
P35761 — 1.000 P35761 →
Q8AYG3 — 0.994 Q8AYG3 →
B2GUY1 — 0.990 B2GUY1 →
Q2QMH1 — 0.989 Q2QMH1 →
Q8WZ64 — 0.988 Q8WZ64 →
O94235 — 0.988 O94235 →
P62292 — 0.987 P62292 →
Q8RXT4 — 0.987 Q8RXT4 →
Q68FF0 — 0.987 Q68FF0 →
Q8BZ05 — 0.987 Q8BZ05 →
P62291 — 0.987 P62291 →
Q08AX9 — 0.987 Q08AX9 →
Q9FT70 — 0.986 Q9FT70 →
Q6GN21 — 0.986 Q6GN21 →
Q6YY75 — 0.986 Q6YY75 →
Q6PIW4 — 0.986 Q6PIW4 →
Q6DDJ5 — 0.986 Q6DDJ5 →
Q4R8Y1 — 0.986 Q4R8Y1 →
Q9FY74 — 0.986 Q9FY74 →
CDC7 Cell division cycle 7-related protein kinase 0.986 landscape →
Q5HZN1 — 0.986 Q5HZN1 →
BRDT Bromodomain testis-specific protein 0.985 landscape →
BLM RecQ-like DNA helicase BLM 0.985 landscape →
BUB1 Mitotic checkpoint serine/threonine-protein kinase BUB1 0.985 landscape →
Q8RX66 — 0.985 Q8RX66 →
Q9NQW6 — 0.985 Q9NQW6 →
P62290 — 0.985 P62290 →
Q94CU5 — 0.985 Q94CU5 →
A2VDZ4 — 0.985 A2VDZ4 →